Navigation Links
ICBS acquires 30% interest in Bacteria Bank Ltd.
Date:10/30/2007

NEW YORK and MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ICBS Limited (PINKSHEETS: ICBM), today announced the acquisition of 30% interest in Bacteria Bank Ltd.

Bacteria Bank Ltd., is a Bio medical company that owns over ten thousand cryogenically stored bacteria for use in medical research, located in Montreal Canada. The company is headed by Dr. Karl Weiss a world renowned bacteriologist.

Dr. Karl Weiss is a Microbiologist and Infectious Diseases Specialist at Maisonneuve-Rosemont Hospital in Montreal . He is also Associate Clinical Professor at the Faculty of Medicine at University of Montreal , and the director of pharmacological research at Maisonneuve-Rosemont hospital. He is also an associate member of the division of infectious diseases at the Jewish General Hospital in Montreal , and an adjunct-professor of Medicine at McGill University.

Bacteria bank has a unique collection of over 10,000 frozen bacteria which can be used for many different purposes.

1. susceptibility testing of potentially promising anti-microbial

agents developed by biotech companies or researchers in

universities.

2. susceptibility testing of new antibiotics against specific and

emerging pathogens such as MRSA ( Methicillin resistant

Staphyloccocus aureus), VRE ( Vancomycin Resistant Enterococcus).

3. susceptibility testing against a wide array of Gram negative

agents ( E. coli, Salmonella, shigella, and other gastro-

intestinal pathogens responsible for million of deaths every year

in the world)

4. susceptibility testing of new agents against Streptococcus

pneumoniae responsible for the majority of sinusitis, otitis

media, pneumonia and some forms of bronchitis. In North America

only, there are over 300 million of antibiotic prescriptions in

the outpatients setting, and S.pneumonie is the number one target

overall by far.

5. bacteria useful for the development of newly designed genetically

derived products ( human and animal hormones, growth factors,

cytokines...)

6. bacteria useful for teaching purposes ( Pharmaceutical companies,

universities and medical schools)

Speaking from the corporate head office in Montreal, Garth McIntosh, President &CEO of ICBS said, " This acquisition will further strengthen our position in the Bio medical industry". ICBS also owns 100% of Canadian Bio Med Systems Ltd. McIntosh further stated " I want to thank all of our shareholders that have supported us in the past year, we are working very hard to make this a profitable year for all. Thank you all for your encouragement and support".

You can visit them at: http://www.bacteriabank.com

This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.


'/>"/>
SOURCE INTER CANADIAN BUSINESS SERVICE
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):